Researchers at the Hong Kong University of Science and Technology have unveiled a pioneering AI model called MOME for non-invasive breast cancer diagnosis.

Using China's largest multiparametric MRI breast cancer dataset, MOME performs at a level comparable to seasoned radiologists and is currently undergoing clinical trials in more than ten hospitals.

Among the institutions participating in the validation phase are Shenzhen People's Hospital, Guangzhou First Municipal People's Hospital, and Yunnan Cancer Center. Early results show that MOME excels in predicting response to pre-surgical chemotherapy.

The development highlights the region's growing capabilities in medtech innovation and could reshape diagnostic strategies for breast cancer across Asia. MOME's clinical success may also pave the way for similar AI-led models in oncology.